A Randomized Multicenter Phase II Study Identifying Hormone Sensivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women

Trial Profile

A Randomized Multicenter Phase II Study Identifying Hormone Sensivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Anastrozole (Primary) ; Fulvestrant (Primary)
  • Indications Early breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms NIMFEA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jun 2016 Results published in the Cancer
    • 08 Dec 2012 Results presented at the 35th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top